In Shorts
- The 2025 Nobel Prize in Medicine has been jointly awarded to three scientists for their seminal work on “immune tolerance.”
- Their research identified key cells and mechanisms, including regulatory T-cells, that stop the body’s immune system from self-attack.
- This foundational science paves the way for revolutionary new therapies for autoimmune disorders like multiple sclerosis and cancer.
STOCKHOLM, October 2025 – The Nobel Assembly at the Karolinska Institutet has today answered one of immunology’s most pressing questions: how does our body’s defense system know not to turn on itself? The 2025 Nobel Prize in Physiology or Medicine has been jointly awarded to Mary E. Brunkow, Fred Ramsdell, and the pioneering Shimon Sakaguchi for their collective “discoveries concerning immune tolerance,” a fundamental process that maintains the delicate balance between health and disease.
For decades, the scientific community understood the immune system as a powerful army designed to fight foreign invaders. However, a crucial piece of the puzzle was missing. What prevents this army from mistakenly launching an assault on the body’s own cells, leading to a civil war within? The work of this year’s laureates has provided the definitive answer, uncovering the precise biological mechanisms that enforce peace.
The Guardians of the Self: Unlocking the Role of Regulatory T-Cells
The journey began with the foundational work of Professor Shimon Sakaguchi, who is widely credited with identifying and characterizing a specific class of lymphocytes known as regulatory T-cells, or T-regs. He demonstrated that these cells act as the immune system’s master peacekeepers, patrolling the body and actively suppressing overzealous immune responses that could target healthy tissue.
Building directly upon this, the critical contributions of Mary E. Brunkow and Fred Ramsdell came into play. Their collaborative research was instrumental in identifying the FOXP3 gene as the “master switch” responsible for the development and function of these vital T-reg cells. A defect in this single gene, they showed, leads to a catastrophic failure of immune tolerance, resulting in severe, widespread autoimmune disease.
A New Era for Medicine: From Autoimmunity to Cancer Immunotherapy
The implications of this research are staggering. By understanding the “brakes” of the immune system, scientists now have a new roadmap for treating a host of conditions.
In autoimmune diseases like type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, the goal is to boost the function of T-regs to calm the erroneous attack. Conversely, in the fight against cancer, researchers are exploring ways to temporarily inhibit T-reg activity in the tumor microenvironment. This allows the body’s natural “killer” T-cells to break through the cancer’s defenses and eliminate the tumor more effectively.
In a statement, the Nobel Committee emphasized the profound impact of the laureates’ work: “The discoveries of Brunkow, Ramsdell, and Sakaguchi have not only solved a central problem in immunology but have also established a new paradigm for therapeutic intervention. They have provided us with the tools to either reinforce or dismantle the body’s tolerance mechanisms, opening up vast and promising frontiers in medicine.”
The awarding of this year’s prize to these three visionaries underscores a monumental shift from simply understanding disease to mastering the body’s own sophisticated rules of engagement, heralding a future where we can more precisely guide the immune system toward health.
Leave a Reply